Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN Exclusives

GEN Exclusives provide you with unique, in-depth, and critical coverage of key industry developments, market moving events, and scientific advances, as well as interviews with life science thought leaders. Also included are feature articles from GEN’s print edition.

The Lists

More »
Sep 26, 2016

Top 25 Biotech Companies of 2016

Wall Street Decline Takes Its Toll on Market Capitalizations

Top 25 Biotech Companies of 2016

The total market capitalization of the 25 companies on this year’s list has slid 14.5%, yet this year’s total is still 5.6% above the combined $990.89 billion market cap of the Top 25 Biotech Companies of 2014.

  • A year after biotech stocks began trending down, as investors retreated from the markets based on fears that public anger over rising drug costs would lead to price curbs imposed by Washington, the results can be seen in this year’s GEN list of Top 25 Biotech Companies.

    The total market capitalization of the 25 companies on this year’s list has slid 14.5%, to 1.047 trillion, from $1.225 trillion last year. Yet this year’s total is still 5.6% above the combined $990.89 billion market cap of the Top 25 Biotech Companies of 2014, so investors who stuck out the volatile biotech market of the past year have something to show for their endurance.

    Following is a list of 25 biotech companies, ranked by their market cap as of September 6 as furnished by the exchanges on which they trade their shares, or by other publicly available sources.

    The minimum market cap of GEN Top-25 biotech companies this time around is just over $7 billion, compared with just under $10 billion a year ago, and $2.3 billion for the lowest of the Top 25 Biotech Companies of 2013, the first year GEN published this list.

    While six biotechs showed market-cap gains, most companies listed lost market cap compared with 2015. Valeant Pharmaceuticals International showed the most erosion, falling from #6 to #22, reflecting the company’s sharp decline of its stock price—from $257.53 on July 1, 2015, to $30.27 on September 7—following a series of problems that include lawsuits over the pricing of its drugs, and the disclosure that the company used specialty pharmacies to store inventory and record the transactions as sales. 

    One company that would have placed #21 this year, Medivation, was not included this year because it is being acquired by Pfizer for $14 billion, in a deal expected to close by year’s end.

  • #25. Seattle Genetics

    $6.81 billion
    NASDAQ (SGEN) 

  • #24. Alkermes

    $7.19 billion
    NASDAQ (ALKS)

  • #23. Jazz Pharmaceuticals

    $7.34 billion
    NASDAQ (JAZZ)

  • #22. Dr. Reddy’s Laboratories

    $7.87 billion
    NYSE (RDY)

  • #21. Valeant Pharmaceuticals International

    $10.49 billion
    NYSE (VRX)

  • #20. Perrigo

    $12.93 billion
    NYSE (PRGO)

  • #19. Sinopharm Group

    $14.29 billion (HKD 110.82 billion)
    Hong Kong Exchange (1099)

  • #18. Incyte

    $15.53 billion
    NASDAQ (INCY)

  • #17. UCB

    $15.58 billion (€13.87 billion)
    Euronext Brussels (UCB)

  • #16. BioMarin Pharmaceutical

    $15.60 billion
    NASDAQ (BMRN)

  • #15. Actelion

    $18.57 billion (CHF 18.01 billion)
    SIX Swiss Exchange (ATLN)

  • #14. Mylan

    $21.61 billion
    NASDAQ (MYL)

  • #13. Vertex Pharmaceuticals

    $23.70 billion
    NASDAQ (VRTX)

  • #12. Alexion Pharmaceuticals

    $27.96 billion
    NASDAQ (ALXN)

  • #11. Sun Pharmaceutical Industries

    $28.30 billion (INR 1.88 trillion)
    National Stock Exchange of India (SUNPHARMA)

  • #10. CSL

    $36.06 billion (A$47.03 billion)
    ASX (CSL)

  • #9. Regeneron Pharmaceuticals

    $41.90 billion
    NASDAQ (REGN)

  • #8. Teva

    $46.53 billion
    NYSE (TEVA)

  • #7. Shire

    $57.44 billion (£43.11 billion)
    London Stock Exchange (SHP)

  • #6. Biogen

    $68.40 billion
    NASDAQ (BIIB)

  • #5. Celgene

    $82.95 billion
    NASDAQ (CELG)

  • #4. Allergan

    $93.54 billion
    NYSE (AGN)

  • #3. Gilead Sciences

    $102.93 billion
    NASDAQ (GILD)

  • #2. Novo Nordisk

    $116.09 billion
    NYSE (NVO)

  • #1. Amgen

    $127.35 billion
    NASDAQ (AMGN)


Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »